Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AAM Calls Out Threat Of Consolidation Among Purchasers

Letter To Authorities Accuses Buying Groups And PBMs Of Anticompetitive Activities

Executive Summary

Drug buying groups and pharmacy benefit managers are leaving generic drug producers unable to compete even when they have viable products due to concentration of buyer power, the Association for Accessible Medicines has highlighted.

You may also be interested in...



Sawai Ends American Dream With Upsher-Smith Sale

Japanese generics giant Sawai is pulling out of the US market, agreeing a deal to divest its Upsher-Smith business to Taiwan’s Bora Pharmaceuticals in a deal worth a little over $200m. As Sawai explained its rationale for the move, Bora pointed to “significant opportunities” for its TWi commercial prescription unit arising from the acquisition.

Zydus Looks To Major US Buyer For New North American Head

Zydus Lifesciences has named Punit Patel, former president of CVS and Cardinal’s generics buying group Red Oak Sourcing, as the company’s new president and CEO for North America.

AAM Calls For Congress And FDA To End Shortages By Easing Up On Generics Quality, Pricing

Remote inspection alternatives could allow quicker resolution of quality issues that are holding up US imports, says association for generic drug manufacturers. AAM adds that adjusting a Medicaid inflation penalty could relieve unfair price pressures.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151757

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel